Verified by Psychology Today

Devon Frye

About

Devon Frye is a Senior Associate Editor at Psychology Today. Prior to joining the PT staff, she spent four years at ADDitude magazine, where she reported on ADHD, learning disabilities, and related conditions. She has worked for Country Living and Scholastic and written for Mic, Shoeleather Magazine, and other publications.

Recent Posts
What to Talk About in Therapy
Choosing which topics to bring up in therapy—and which to avoid—can feel daunting for someone new to the process. Here’s what clients should keep in mind.
Why Apologies Are So Hard, and So Necessary

It’s not easy to hold yourself accountable for harm you’ve caused others. A new book explains why, and outlines a plan for offering sincere, restorative apologies.

It’s not easy to hold yourself accountable for harm you’ve caused others. A new book explains why, and outlines a plan for offering sincere, restorative apologies.

The Hot Hand: Does Success Lead to More Success?

Sports reporter Ben Cohen searches for the existence of the “hot hand” in his new book on the science of streaks.

Sports reporter Ben Cohen searches for the existence of the “hot hand” in his new book on the science of streaks.

Gender Gap in Teen Suicide Is Narrowing, Study Finds

The disproportionate increase in female suicide is alarming, researchers say, and highlights the need for new, tailored prevention strategies.

The disproportionate increase in female suicide is alarming, researchers say, and highlights the need for new, tailored prevention strategies.

Should We Worry About Cannabis Use Causing Psychosis?

A new study finds further evidence of an association between cannabis use—particularly heavy use—and a risk of developing psychosis. But questions about causality remain.

A new study finds further evidence of an association between cannabis use—particularly heavy use—and a risk of developing psychosis. But questions about causality remain.

New Drug for Depression, Derived From Ketamine, Is Approved

Esketamine will soon be available to patients with treatment-resistant depression. While its novel formula achieved FDA approval, some are voicing concerns about limited data.

Esketamine will soon be available to patients with treatment-resistant depression. While its novel formula achieved FDA approval, some are voicing concerns about limited data.